Vanguard Group Inc. Has $3.50 Billion Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Key Points

• Vanguard Group Inc. has reduced its holdings in IQVIA Holdings Inc. by 1.5%, owning approximately 19.8 million shares worth about $3.50 billion as of the end of the last quarter.
• Several institutional investors made significant changes to their positions in IQVIA, with Pacer Advisors Inc. increasing its stake by over 5,000% during the first quarter.
• Analysts have mixed ratings for IQVIA, with price targets ranging from $165 to $232, but the average rating suggests a Moderate Buy with a target price of $228.62.

Vanguard Group Inc. decreased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 1.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 19,838,315 shares of the medical research company's stock after selling 293,419 shares during the quarter. Vanguard Group Inc. owned 11.47% of IQVIA worth $3,497,495,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in IQV. Pacer Advisors Inc. grew its stake in shares of IQVIA by 5,036.1% during the first quarter. Pacer Advisors Inc. now owns 871,704 shares of the medical research company's stock worth $153,681,000 after buying an additional 854,732 shares during the last quarter. Canada Pension Plan Investment Board boosted its holdings in shares of IQVIA by 20.0% during the 4th quarter. Canada Pension Plan Investment Board now owns 4,282,024 shares of the medical research company's stock valued at $841,461,000 after acquiring an additional 712,958 shares in the last quarter. D. E. Shaw & Co. Inc. grew its position in IQVIA by 211.2% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 965,302 shares of the medical research company's stock worth $189,691,000 after acquiring an additional 655,153 shares during the last quarter. Marshall Wace LLP raised its position in IQVIA by 85.4% in the fourth quarter. Marshall Wace LLP now owns 954,294 shares of the medical research company's stock valued at $187,528,000 after purchasing an additional 439,649 shares during the last quarter. Finally, Cadian Capital Management LP acquired a new stake in shares of IQVIA during the fourth quarter valued at about $78,604,000. Institutional investors own 89.62% of the company's stock.

Insider Buying and Selling

In related news, insider Keriann Cherofsky sold 549 shares of the stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the transaction, the insider directly owned 2,910 shares in the company, valued at $557,352.30. This trade represents a 15.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Eric Sherbet sold 5,800 shares of the business's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the sale, the insider owned 27,178 shares of the company's stock, valued at $5,165,178.90. This trade represents a 17.59% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on IQV. JPMorgan Chase & Co. lowered their price objective on IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a research note on Monday, May 19th. UBS Group upped their price target on shares of IQVIA from $185.00 to $225.00 and gave the company a "buy" rating in a research report on Wednesday, July 23rd. Citigroup reiterated a "neutral" rating on shares of IQVIA in a report on Thursday, May 22nd. Barclays increased their price objective on IQVIA from $165.00 to $185.00 and gave the company an "equal weight" rating in a report on Wednesday, July 23rd. Finally, Mizuho lifted their target price on IQVIA from $190.00 to $225.00 and gave the stock an "outperform" rating in a report on Friday, July 25th. Seven research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat, IQVIA has an average rating of "Moderate Buy" and an average target price of $228.62.

IQVIA Stock Up 0.8%

Shares of NYSE IQV opened at $178.99 on Friday. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45. The firm has a market cap of $30.43 billion, a PE ratio of 25.90, a P/E/G ratio of 1.95 and a beta of 1.30. The company's fifty day simple moving average is $164.68 and its 200 day simple moving average is $169.75. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last issued its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating the consensus estimate of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%. The company had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. During the same period last year, the business posted $2.64 EPS. The firm's revenue for the quarter was up 5.3% compared to the same quarter last year. As a group, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.